Ethinylestradiol30?g-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?

ABSTRACT: We are hereby investigating for the first time the effect of the association ethinylestradiol30?g-drospirenone 3mg (DRP/EE30?g) plus metformin and weight loss on endothelial status and C-reactive protein (hsCRP) levels in polycystic ovary syndrome (PCOS).25 young women with PCOS (mean age 22.76?±?0.83 years, body mass index (BMI): 28.44?±?6.23) who completed the study were prospectively evaluated. The oral contraceptive- DRP/EE30?g (21 days/month) and metformin (1700 mg daily) were administered for 6 months to the PCOS group. Additionally, the 15 overweight and obese patients (BMI?>?25 kg/m2) were instructed in a diet of no more than 1500 cal daily. Primary outcome measures were surrogate markers of cardiovascular disease and included endothelial function, i.e. flow-mediated dilatation (FMD) on the brachial artery and endothelin-1 levels, as well as hsCRP concentrations, body composition (measured by whole-body dual-energy X-ray-absorptiometry) and insulin resistance. Variables were assessed at baseline, as well as after our medical intervention.The combination between DRP/EE30?g plus metformin combined with weight loss triggered a significant improvement in the FMD values (FMD-PCOSbasal 3.48?±?1.00 vs FMD-PCOS6 months7.43?±?1.04, p?=?0.033), as well as body composition and insulin insensitivity (p?

SUBMITTER: Ilie IR 

PROVIDER: S-EPMC3413550 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature